A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting the programmed-cell death-1 immune checkpoint, pembrolizumab and nivolumab, have been rarely reported to induce the development of type 1 diabetes mellitus. Here we describe a case of a patient who developed antibody-positive type 1 diabetes mellitus following treatment with pembrolizumab in combination with systemic chemotherapy for metastatic adenocarcinoma of the lung. We will also provide a brief literature review of other rarely reported cases of type 1 diabetes presenting after treatment with pembrolizumab and nivolumab, as well as discussion regarding potential mechanisms of this adverse effect and its importance as these drugs continue to become even more widespread.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [116]
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Genetics of the HLA Region in the Prediction of Type 1 Diabetes
Noble, J. A., & Valdes, A. M. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0223-x · Cited by 460
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 401
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Interferon-α initiates type 1 diabetes in nonobese diabetic mice
Li, Q., Xu, B., Michie, S. A., Rubins, K. H., Schreriber, R. D., & McDevitt, H. O. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806439105 · Cited by 182
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Gaudy, C., Clévy, C., Monestier, S., Dubois, N., Préau, Y., Mallet, S., Richard, M.-A., Grob, J.-J., Valéro, R., & Béliard, S. (2015) · Diabetes Care · doi:10.2337/dc15-1331 · Cited by 159
Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy
Okamoto, M., Okamoto, M., Gotoh, K., Masaki, T., Ozeki, Y., Ando, H., Anai, M., Sato, A., Yoshida, Y., Ueda, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12531 · Cited by 155
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Martín-Liberal, J., Furness, A. J. S., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1689-1 · Cited by 137
Mechanisms of PDL1-mediated regulation of autoimmune diabetes
Guleria, I., Bupp, M. G., Dada, S., Fife, B. T., Tang, Q., Ansari, M. J., Trikudanathan, S., Vadivel, N., Fiorina, P., Yagita∥, H., et al. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.05.013 · Cited by 134
Ipilimumab-induced autoimmune adrenalitis
Min, L., & Ibrahim, N. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70031-7 · Cited by 112
Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis
Fabris, P., Betterle, C., Greggio, N. A., Zanchetta, R., Bosi, E., Biasin, M. R., & de Lalla, F. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80328-0 · Cited by 112
Fujisawa, R., Haseda, F., Tsutsumi, C., Hiromine, Y., Noso, S., Kawabata, Y., Mitsui, S., Terasaki, J., Ikegami, H., Imagawa, A., et al. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12603 · Cited by 103
Hansen, E., Sahasrabudhe, D. M., & Sievert, L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1835-4 · Cited by 93
Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes
Miyoshi, Y., Ogawa, O., & Oyama, Y. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.155 · Cited by 90
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 64
Kochupurakkal, N. M., Kruger, A. J., Tripathi, S., Zhu, B., Adams, L. T., Rainbow, D. B., Rossini, A., Greiner, D. L., Sayegh, M. H., Wicker, L. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089561 · Cited by 60
The role of interferon alpha in initiation of type I diabetes in the NOD mouse
Li, Q., & McDevitt, H. O. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.04.010 · Cited by 53
Perri, V., Russo, B., Crinò, A., Schiaffini, R., Giorda, E., Cappa, M., Rosado, M., & Fierabracci, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922584 · Cited by 49
Case of type 1 diabetes associated with less‐dose nivolumab therapy in a melanoma patient
Teramoto, Y., Nakamura, Y., Asami, Y., Imamura, T., Takahira, S., Nemoto, M., Sakai, G., Shimada, A., Noda, M., & Yamamoto, A. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13486 · Cited by 47
Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis
Shiba, T., Morino, Y., Tagawa, K., Fujino, H., & Unuma, T. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01188-9 · Cited by 41
Chianese-Bullock, K. A., Woodson, E. M. H., Tao, H., Boerner, S. A., Smolkin, M., Grosh, W. W., Neese, P. Y., Merrill, P., Petroni, G. R., & Slingluff, C. L. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000171314.00924.2b · Cited by 40
Abrupt onset of diabetes during interferon‐alpha therapy in patients with chronic hepatitis C
Recasens, M., Aguilera, E., Ampurdanés, S., Tapias, J. M. S., Simó, O., Casamitjana, R., & Conget, I. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00562.x · Cited by 39
Yamazaki, M., Sato, A., Takeda, T., & Komatsu, M. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2656 · Cited by 29
Diabetes mellitus induced by low-dose interleukin-2
Soni, N., Meropol, N. J., Porter, M., & Caligiuri, M. A. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050304 · Cited by 17
Kawazoe, T., Araki, M., Lin, Y., Ogawa, M., Okamoto, T., Yamamura, T., Wakakura, M., & Murata, M. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7771 · Cited by 15
Lv, Y.-Y., Shi, B., & Guo, H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4713 · Cited by 7
Spain, L. A., Larkin, J., & Martín-Liberal, J. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1845-2 · Cited by 6
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“There have also been reports of patients experiencing exacerbation of pre-existing autoimmune conditions such as psoriasis (91, 92, 100) or developing new ones such as type 1 diabetes mellitus (101).”
BackgroundEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T. K., Grimm, M.-O., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 331
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T., Bravenboer, B., Van der Auwera, B. J., Gorus, F. K., Roep, B. O., Aspeslagh, S., Neyns, B., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0291 · Cited by 275
“Additionally, the authors reviewed the reference lists of the included articles (4, 13-68) and identified 5 additional cases (69-72).”
Background
Metadata
- Authors
- Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F.
- Affiliations
- Northwestern University (US)
- University of Virginia (US)
- Corresponding author
- Chae, Young Kwang
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2016-10-19
- Volume
- 66
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028603
- OpenAlex
- W2532961791
- Cited by
- 121
- References
- 34
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 18 · 2017: 20
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pembrolizumab, type 1 diabetes, immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, nivolumab, ipilimumab, lung adenocarcinoma, metastatic cancer, systemic chemotherapy, autoimmune diabetes, drug-induced diabetes
- MeSH terms
- Aged, Antineoplastic Combined Chemotherapy Protocols, Diabetes Mellitus, Type 1, Humans, Lung Neoplasms, Male, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.